Clinical Trial Update: A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing safety and efficacy of ABT-450/r/ABT-267 and ABT-333 in chronic hepatitis C; study completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-333 (ABT-333)
• ABT-450/Ritonavir/ABT-267 (ABT-450/ritonavir/ABT-267)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Chronic Hepatitis C Infection | Phase 3 | Status: COMPLETED | Results posted: 2015-01-06